Biomedical Diagnostics Series

2023 Biomedical Diagnostics Series

Biomedical Diagnostics Global series

Diagnostics: Fulfilling Its Potential

Join colleagues, health providers and researchers online for the inaugural 2023 Biomedical Diagnostics Global Discussion Series in collaboration with Thermo Fisher Scientific, a three-part series taking place June 14, September 13 and November 1, 2023. 

The series of dynamic discussions will take place online. Each discussion will involve leading national experts in the chosen topic. Participants will be able to interact and ask questions as part of the discussion. 

Registration: No cost.


Topics for the 2023 discussion series 

Diagnostics: What do Healthcare Providers Know or Should Know about Diagnostics?

Nov. 15, 2023, 8 a.m. PST/11 a.m. EST/5 p.m. CEST   

How, what and when do physicians/nurses learn about diagnostics? What incentives exist for providers and payers to use or not use testing? What role should diagnostics labs and manufacturers play in physician/healthcare provider education?   


Shami Feinglass

The Aspen Institute

Nathan Ledeboer
Assistant professor of pathology and medical director of clinical microbiology
Medical College of Wisconsin

Tom Miller
Managing partner
GreyBird Ventures

Stan Rose
Managing partner
Rose Ventures

Mara Aspinall, moderator
Professor of practice

ASU College of Health Solutions<


Diagnostics Technologies: Lab of the Future 

Sept. 20, 2023, 8 a.m. PDT/11 a.m. EDT/5 p.m. CEST

What technologies will transform the lab of the future? How should labs best utilize their capacity?  Where are the growth opportunities in the current lab infrastructure? What role does data and informatics play?


Barb Jones
Chief executive officer

Clinical and Laboratory Standards Institute

Stephanie McCalla
Associate professor
Montana State University

Susan Realegeno
Scientific director
Quest Diagnostics

Mara Aspinall, moderator
Professor of practice

ASU College of Health Solutions


Diagnostics for the Healthy: The Screening Paradox

June 14, 2023, 8 a.m. PDT/11 a.m. EDT/5 p.m. CEST 

What are the pros and cons of diagnostic screening from cancer to COVID-19 and beyond? Which tests are being over and underutilized? How can screening be economically feasible? Will we ever have effective screening tests from a single drop of blood?


Dr. Karen Anderson

Biodesign Center for Personalized Diagnostics

Arizona State University

Associate professor of medicine
Mayo Clinic

Bruce J. Tromberg
National Institute of Biomedical Imaging and Bioengineering
National Institutes of Health

Christina Clarke Dur
Epidemiology vice president
Distinguished scientist

Mara Aspinall, moderator
Professor of practice

ASU College of Health Solutions